Cancer

Advancement of Internal Cancer Drug Discovery Program

Published in Drug Law Weekly, May 29th, 2007

Sareum Holdings plc (Sareum) (AIM: SAR), the specialist structure-based drug discovery business, is pleased to announce that it has developed, and filed patent applications on, novel small molecule compounds which show promising activity against two significant cancer drug discovery target types.

These targets are the Aurora and FLT kinases, believed to be key to the regulation of cell division and proliferation, which control different stages in the development of a tumour. It is believed that a drug simultaneously able to inhibit the function of both targets will be more effective against cancer than an inhibitor that acts on a single target. The associated patent...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2007-05-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry